$VISM
VISIUM TECHNOLOGIES, INC.

2023 Q2 Form 10-Q Financial Statement

#000165495423006569 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $737.1K $568.0K
YoY Change 32.82% -56.2%
% of Gross Profit
Research & Development $39.26K $73.76K
YoY Change -54.71% -5.79%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $776.3K $641.7K
YoY Change 20.99% -53.33%
Operating Profit -$641.7K
YoY Change -53.33%
Interest Expense -$46.03K $20.27K
YoY Change -64.41% -115.67%
% of Operating Profit
Other Income/Expense, Net -$90.35K
YoY Change -30.12%
Pretax Income -$819.4K -$732.1K
YoY Change 40.53% -51.33%
Income Tax
% Of Pretax Income
Net Earnings -$965.1K -$732.1K
YoY Change 65.52% -51.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.06 -$0.16
COMMON SHARES
Basic Shares Outstanding 10.60M shares 4.335M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.980K $46.75K
YoY Change -92.71% -86.74%
Cash & Equivalents $9.982K $46.75K
Short-Term Investments
Other Short-Term Assets $17.50K
YoY Change 499.32%
Inventory
Prepaid Expenses $0.00 $17.50K
Receivables
Other Receivables
Total Short-Term Assets $9.982K $64.25K
YoY Change -92.71% -81.93%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $9.982K $64.25K
Total Long-Term Assets $0.00 $0.00
Total Assets $9.982K $64.25K
YoY Change -92.71% -81.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $845.5K $661.2K
YoY Change 41.75% 43.45%
Accrued Expenses $1.920M $1.625M
YoY Change 88.36% 52.4%
Deferred Revenue
YoY Change
Short-Term Debt $1.318M $1.775M
YoY Change 2.98% 38.35%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.263M $4.316M
YoY Change 45.48% 43.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.263M $4.316M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.263M $4.316M
YoY Change 45.48% 43.16%
SHAREHOLDERS EQUITY
Retained Earnings -$59.87M -$59.05M
YoY Change 5.85% 5.49%
Common Stock $2.987K $559.00
YoY Change 937.15% -99.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.253M -$4.251M
YoY Change
Total Liabilities & Shareholders Equity $9.982K $64.25K
YoY Change -92.71% -81.93%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$965.1K -$732.1K
YoY Change 65.52% -51.33%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$71.15K -$174.6K
YoY Change -85.24% -78.68%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 34.38K 190.0K
YoY Change -87.09% -76.54%
NET CHANGE
Cash From Operating Activities -71.15K -174.6K
Cash From Investing Activities
Cash From Financing Activities 34.38K 190.0K
Net Change In Cash -36.77K 15.36K
YoY Change -82.95% -271.43%
FREE CASH FLOW
Cash From Operating Activities -$71.15K -$174.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2903804 shares
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54782670 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59050036 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4251487 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64250 usd
CY2023Q1 us-gaap Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
72500 usd
CY2022Q2 us-gaap Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175707 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
274614 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
641734 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1374900 usd
us-gaap Operating Expenses
OperatingExpenses
1637267 usd
us-gaap Operating Expenses
OperatingExpenses
4035850 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-641734 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1374900 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1637267 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001082733
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q2 vism Common Stock Share Authorized
CommonStockShareAuthorized
1000000000 shares
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
437093 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-25753
dei Entity Registrant Name
EntityRegistrantName
VISIUM TECHNOLOGIES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0449667
dei Entity Address Address Line1
EntityAddressAddressLine1
4094 MAJESTIC LANE
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 360
dei Entity Address City Or Town
EntityAddressCityOrTown
FAIRFAX
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
22033
dei City Area Code
CityAreaCode
703
dei Local Phone Number
LocalPhoneNumber
273-0383
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10603284 shares
CY2023Q1 vism Notes Payable Net Of Discount
NotesPayableNetOfDiscount
11738 usd
CY2022Q2 vism Notes Payable Net Of Discount
NotesPayableNetOfDiscount
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7380323 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
-4035850 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-50384 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-76707 usd
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5588656 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2896385 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
559 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
CY2022Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
567979 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1296611 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1461560 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3761236 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73755 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78289 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-84246 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-20632 usd
CY2023Q1 vism Derivative Liability Expense
DerivativeLiabilityExpense
-4634 usd
CY2022Q1 vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
-62773 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15068 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-519993 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
20265 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
52587 usd
us-gaap Interest Expense
InterestExpense
187205 usd
us-gaap Interest Expense
InterestExpense
554262 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90354 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-129294 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-854217 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-574624 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-732085 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1504194 usd
us-gaap Net Income Loss
NetIncomeLoss
-2491484 usd
us-gaap Net Income Loss
NetIncomeLoss
-4610474 usd
CY2023Q1 vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.16
CY2022Q1 vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.55
vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-0.72
vism Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
-1.86
CY2023Q1 vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
4658570 shares
CY2022Q1 vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
2750423 shares
vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
3454032 shares
vism Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
2477833 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3997400 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
18084 usd
CY2023Q1 vism Shares Issued As Compensation To Employees Amount
SharesIssuedAsCompensationToEmployeesAmount
71300 usd
CY2023Q1 vism Shares Issued As Compensation To Directors And Officers Amount
SharesIssuedAsCompensationToDirectorsAndOfficersAmount
161200 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
213418 usd
CY2023Q1 vism Commitment Shares Issued Pursuant To Financing Amount
CommitmentSharesIssuedPursuantToFinancingAmount
14000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-732085 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4251487 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2793558 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
36956 usd
vism Shares Issued As Compensation To Employees Amount
SharesIssuedAsCompensationToEmployeesAmount
144150 usd
vism Shares Issued As Compensation To Directors And Officers Amount
SharesIssuedAsCompensationToDirectorsAndOfficersAmount
361013 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
186972 usd
vism Shares Issued For Conversion Of Notes Payable And Accrued Interest Amount
SharesIssuedForConversionOfNotesPayableAndAccruedInterestAmount
290464 usd
vism Commitment Shares Issued Pursuant To Financing Amount
CommitmentSharesIssuedPursuantToFinancingAmount
14000 usd
vism Shares Issued For Exercise Of Warrants Amount
SharesIssuedForExerciseOfWarrantsAmount
0 usd
us-gaap Net Income Loss
NetIncomeLoss
-2491484 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4251487 usd
CY2022Q1 vism Shares Issued As Compensation Amount
SharesIssuedAsCompensationAmount
241400 usd
CY2022Q1 vism Amortization Of Deferred Compensation
AmortizationOfDeferredCompensation
40524 usd
CY2022Q1 vism Commitment Shares Pursuant To Financing Amount
CommitmentSharesPursuantToFinancingAmount
165802 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1504194 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-2659210 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-2837187 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1110631 usd
vism Shares Issued As Compensation Amount
SharesIssuedAsCompensationAmount
1059400 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
831048 usd
vism Commitment Shares Issued Pursuant To Financings Amount
CommitmentSharesIssuedPursuantToFinancingsAmount
165802 usd
vism Shares Issued Pursuant To Sale Of Common Stock Amount
SharesIssuedPursuantToSaleOfCommonStockAmount
1500000 usd
vism Shares Issued For Exercise Of Warrants Amount
SharesIssuedForExerciseOfWarrantsAmount
0 usd
vism Amortization Of Deferred Compensation
AmortizationOfDeferredCompensation
121572 usd
us-gaap Net Income Loss
NetIncomeLoss
-4610474 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-2659210 usd
us-gaap Net Income Loss
NetIncomeLoss
-2491484 usd
us-gaap Net Income Loss
NetIncomeLoss
-4610474 usd
us-gaap Share Based Compensation
ShareBasedCompensation
542149 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2170031 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
83218 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
388842 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
-62773 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
17500 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-52500 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-150008 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-60640 usd
vism Derivative Liability Expense
DerivativeLiabilityExpense
0 usd
vism Derivative Gain Loss On Derivatives Net
DerivativeGainLossOnDerivativesNet
-84246 usd
vism Derivative Gain Loss On Derivatives Net
DerivativeGainLossOnDerivativesNet
-20362 usd
vism Amortization Of Deferred Compensation
AmortizationOfDeferredCompensation
0 usd
vism Amortization Of Deferred Compensation
AmortizationOfDeferredCompensation
121572 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-519993 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
37812 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
35092 usd
vism Increase Decrease In Discount On Notes Payable
IncreaseDecreaseInDiscountOnNotesPayable
0 usd
vism Increase Decrease In Discount On Notes Payable
IncreaseDecreaseInDiscountOnNotesPayable
-13958 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
576045 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
5265 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-452740 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1742572 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1500000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
115000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
140000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
810000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
150000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
225000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
72500 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
362500 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1970000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-90240 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
227428 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136990 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125166 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46750 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
352594 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
22011 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
vism Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest
IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest
290464 usd
vism Issuance Of Common Stock For Conversion Of Notes Payable And Accrued Interest
IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterest
831048 usd
vism Commitment Shares Issued For Financing
CommitmentSharesIssuedForFinancing
14000 usd
vism Commitment Shares Issued For Financing
CommitmentSharesIssuedForFinancing
165802 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
186972 usd
vism Warrants Issued On Extinguishment Of Debt
WarrantsIssuedOnExtinguishmentOfDebt
0 usd
CY2023Q1 vism Common Stock Shares Authorized To Be Issued
CommonStockSharesAuthorizedToBeIssued
1000000000 shares
CY2023Q1 vism Common Stock Share Authorized
CommonStockShareAuthorized
10000000000 shares
us-gaap Profit Loss
ProfitLoss
-2491484 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-452740 usd
CY2023Q1 vism Working Capital Deficit
WorkingCapitalDeficit
4251487 usd
us-gaap Fiscal Period
FiscalPeriod
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fiscal year ends on June 30. References to fiscal year 2023, for example, refer to the fiscal year ending June 30, 2023.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements' the reporting amounts of revenues and expenses, and the valuation of shares issued for services during the reported period. Actual results will differ from those estimates. Included in these estimates are assumptions used in Cox, Ross &amp; Rubinstein Binomial Tree stock-based compensation valuation methods, such as expected volatility, risk-free interest rate, and expected dividend rate and in the valuation allowance of deferred tax assets and derivative liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 pandemic and related developments have created and may continue to create significant uncertainty in global financial markets, which may decrease technology spending, depress demand for our products and harm our business and results of operations. As of the date of issuance of the financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates or judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, which could be recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our financial statements.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is subject to a concentration of credit risk from cash.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash account is held at a financial institution and is insured by the Federal Deposit Insurance Corporation, or FDIC, up to $250,000. The Company did not have cash on deposit in excess of such limit on March 31, 2023 and June 30, 2022.</p>
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2021Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
35297 usd
CY2022 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
62773 usd
CY2022 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
84246 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3454032 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2424513 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4846219 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
71045 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
11348 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
11348 shares
vism Incremental Common Shares Attributable To Common Stock Option
IncrementalCommonSharesAttributableToCommonStockOption
2222 shares
vism Incremental Common Shares Attributable To Common Stock Option
IncrementalCommonSharesAttributableToCommonStockOption
5926 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
66781 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
5049 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
8380602 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2517881 shares
vism Annually Prepaid License Fee
AnnuallyPrepaidLicenseFee
70000 usd
us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
17500 usd
CY2023Q1 vism Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.02
vism Convertible Notes Payables
ConvertibleNotesPayables
-84246 usd
vism Convertible Notes Payables
ConvertibleNotesPayables
20362 usd
CY2023Q1 vism Derivative Liabilities Fair Value Assumptions Market Price
DerivativeLiabilitiesFairValueAssumptionsMarketPrice
0.1945
CY2022Q1 vism Derivative Liabilities Fair Value Assumptions Market Price
DerivativeLiabilitiesFairValueAssumptionsMarketPrice
3.645
vism Derivative Liabilities Fair Value Assumptions Expected Dividend Rate
DerivativeLiabilitiesFairValueAssumptionsExpectedDividendRate
0 pure
vism Derivative Liabilities Fair Value Assumptions Expected Dividend Rate
DerivativeLiabilitiesFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
35297 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
62773 usd
vism Loss On Change In Fair Value Of Derivative Liabilities
LossOnChangeInFairValueOfDerivativeLiabilities
84246 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
182316 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
404712 usd
vism Payments Of Accrued Interest
PaymentsOfAccruedInterest
90564 usd
vism Conversion Of Accrued Interest
ConversionOfAccruedInterest
-61200 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
434076 usd
CY2023Q1 vism Convertible Notes Payable1
ConvertibleNotesPayable1
1431790 usd
CY2022Q2 vism Convertible Notes Payable1
ConvertibleNotesPayable1
1487431 usd
CY2023Q1 vism Discount On Convertible Notes Payable
DiscountOnConvertibleNotesPayable
0 usd
CY2022Q2 vism Discount On Convertible Notes Payable
DiscountOnConvertibleNotesPayable
-412944 usd
CY2023Q1 vism Convertible Notes Payable To Related Parties Current
ConvertibleNotesPayableToRelatedPartiesCurrent
1431790 usd
CY2022Q2 vism Convertible Notes Payable To Related Parties Current
ConvertibleNotesPayableToRelatedPartiesCurrent
1074487 usd
CY2023Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1431790 usd
CY2022Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1074487 usd
vism Scheduleofconvertible Notes Payabletabletextblock
ScheduleofconvertibleNotesPayabletabletextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible payable at June 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,487,431</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible notes issued during the nine months ended March 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Conversion of convertible notes payable into common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(204,891 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible payable at March 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,431,790</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q2 vism Convertibles Notes Payable
ConvertiblesNotesPayable
1487431 usd
vism Convertible Notes Issued55
ConvertibleNotesIssued55
149250 usd
vism Conversion Of Convertible Notes Payable Into Common Stock
ConversionOfConvertibleNotesPayableIntoCommonStock
-204891 usd
CY2023Q1 vism Convertibles Notes Payable
ConvertiblesNotesPayable
1431790 usd
vism Value Of Warrants Issued
ValueOfWarrantsIssued
186972 usd
vism Write Off Of Unamortized Debt Discount
WriteOffOfUnamortizedDebtDiscount
317953 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
504925 usd
CY2023Q1 vism Loss On Convertible Notes Payable
LossOnConvertibleNotesPayable
15068 usd
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
976100 shares
vism Totalconvertible Notes Payable Principle Amount
TotalconvertibleNotesPayablePrincipleAmount
204891 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
61200 usd
vism Total Convertible Notes Payable Conversion Expense
TotalConvertibleNotesPayableConversionExpense
10500 usd
vism Total Convertible Notes Payable Adjustment To Fair Value
TotalConvertibleNotesPayableAdjustmentToFairValue
-13873
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
290464 usd
us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.30
CY2023Q1 vism Promissory Notes
PromissoryNotes
343262 usd
vism Schedule Of Promissory Notestabletextblock
ScheduleOfPromissoryNotestabletextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Promissory notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">355,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">205,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Discount on promissory notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,738 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Promissory notes payable, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">343,262</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">205,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q1 vism Promissory Notes Payable
PromissoryNotesPayable
355000 usd
CY2022Q2 vism Promissory Notes Payable
PromissoryNotesPayable
205000 usd
CY2023Q1 vism Discount On Promissory Notes Payable
DiscountOnPromissoryNotesPayable
11738 usd
CY2023Q1 vism Promissory Notes Payable Net
PromissoryNotesPayableNet
343262 usd
CY2022Q2 vism Promissory Notes Payable Net
PromissoryNotesPayableNet
205000 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
vism Reverse Stock Split Outstanding Common Shares
ReverseStockSplitOutstandingCommonShares
3916144800 shares
vism Total Reverse Stock Split Outstanding Common Shares
TotalReverseStockSplitOutstandingCommonShares
2896396 shares
vism Description Of Reverse Stock Split Effect
DescriptionOfReverseStockSplitEffect
This action also reduced the number of authorized common shares of the Company from 10,000,000,000 to 1,000,000,000
vism Description Of Warrant2 Year Life
DescriptionOfWarrant2YearLife
In January and February 2021, we issued 2,268 warrants with a two year life, and fixed exercise prices ranging from $7.425 to $27.00 per share.
vism Description Of Warrant3 Year Life
DescriptionOfWarrant3YearLife
In July and October 2021 we issued 2,781 warrants with a three year life, and fixed exercise prices of $10.3957, $12.285, and $20.385.
CY2022Q3 vism Long Terms Debt Fair Value
LongTermsDebtFairValue
186972 usd
CY2023Q1 vism Warrant Exercisable
WarrantExercisable
66781 shares
CY2023Q1 vism Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price8 E
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice8E
1.89
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
66781 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y1M20D
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.89
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
66781 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.89
CY2023Q1 vism Unrecognized Nonvested Expenses
UnrecognizedNonvestedExpenses
0 usd
vism Plan Terminates Period
PlanTerminatesPeriod
P10Y
vism Options Issued For Purchase
OptionsIssuedForPurchase
11852 usd
CY2023Q1 us-gaap Share Price
SharePrice
20.25
vism Fair Value Of Shares
FairValueOfShares
0.00
vism Options To Purchase Vested Shares
OptionsToPurchaseVestedShares
2222 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
vism Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.0000 pure
CY2022 vism Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.0000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
vism Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term Begining
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermBegining
P3Y29D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P3Y29D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2222 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y29D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
27.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y29D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7407 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
3405000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
40000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1580741 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.34
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1791666 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.31
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
555417 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y9M
vism Stock Based Compensation Expense
StockBasedCompensationExpense
542149 usd
CY2023Q1 us-gaap Due To Officers Or Stockholders Current
DueToOfficersOrStockholdersCurrent
72500 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
vism Common Stock Vested Value
CommonStockVestedValue
40250 usd
vism Common Stock Vested Shares
CommonStockVestedShares
2012500 shares
CY2023Q1 vism Common Stock Shares Vested Average Price Per Share
CommonStockSharesVestedAveragePricePerShare
0.02
CY2023Q2 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
93000 usd

Files In Submission

Name View Source Status
vism-20230331_cal.xml Edgar Link unprocessable
vism-20230331_def.xml Edgar Link unprocessable
0001654954-23-006569-index-headers.html Edgar Link pending
0001654954-23-006569-index.html Edgar Link pending
0001654954-23-006569.txt Edgar Link pending
0001654954-23-006569-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vism-20230331.xsd Edgar Link pending
vism_10q.htm Edgar Link pending
vism_10qimg2.jpg Edgar Link pending
vism_ex311.htm Edgar Link pending
vism_ex312.htm Edgar Link pending
vism_ex321.htm Edgar Link pending
vism_ex322.htm Edgar Link pending
vism-20230331_lab.xml Edgar Link unprocessable
vism-20230331_pre.xml Edgar Link unprocessable
vism_10q_htm.xml Edgar Link completed